Showing results (41-50 of 48) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Breast Cancer Research : BCR|August 8, 2020
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancerLaura Biganzoli, Saverio Cinieri, Rossana Berardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER TrialJoan Albanell, José Manuel Pérez-García, Miguel Gil-Gil, et al.The Oncologist|April 23, 2017
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic SettingDaniele Generali, Filippo Montemurro, Roberto Bordonaro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.Frontiers in Oncology|October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on SurvivalFrancesco Mannavola, Mario Mandala, Annalisa Todisco, et al.NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.Nature Communications|January 3, 2024
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialPaolo A Ascierto, Milena Casula, Jenny Bulgarelli, et al.Journal for Immunotherapy of Cancer|October 16, 2020
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologistsMargaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, et al.Pageof 5